These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37373253)

  • 1. Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice.
    Kunze LH; Ruch F; Biechele G; Eckenweber F; Wind-Mark K; Dinkel L; Feyen P; Bartenstein P; Ziegler S; Paeger L; Tahirovic S; Herms J; Brendel M
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation.
    Biechele G; Blume T; Deussing M; Zott B; Shi Y; Xiang X; Franzmeier N; Kleinberger G; Peters F; Ochs K; Focke C; Sacher C; Wind K; Schmidt C; Lindner S; Gildehaus FJ; Eckenweber F; Beyer L; von Ungern-Sternberg B; Bartenstein P; Baumann K; Dorostkar MM; Rominger A; Cumming P; Willem M; Adelsberger H; Herms J; Brendel M
    Theranostics; 2021; 11(18):8964-8976. PubMed ID: 34522221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases.
    Biechele G; Franzmeier N; Blume T; Ewers M; Luque JM; Eckenweber F; Sacher C; Beyer L; Ruch-Rubinstein F; Lindner S; Gildehaus FJ; von Ungern-Sternberg B; Cumming P; Bartenstein P; Rominger A; Höglinger GU; Herms J; Brendel M
    J Neuroinflammation; 2020 Dec; 17(1):374. PubMed ID: 33317543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning.
    Eckenweber F; Medina-Luque J; Blume T; Sacher C; Biechele G; Wind K; Deussing M; Briel N; Lindner S; Boening G; von Ungern-Sternberg B; Unterrainer M; Albert NL; Zwergal A; Levin J; Bartenstein P; Cumming P; Rominger A; Höglinger GU; Herms J; Brendel M
    J Neuroinflammation; 2020 Jul; 17(1):208. PubMed ID: 32660586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Visualization of Tau Accumulation, Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510.
    Ishikawa A; Tokunaga M; Maeda J; Minamihisamatsu T; Shimojo M; Takuwa H; Ono M; Ni R; Hirano S; Kuwabara S; Ji B; Zhang MR; Aoki I; Suhara T; Higuchi M; Sahara N
    J Alzheimers Dis; 2018; 61(3):1037-1052. PubMed ID: 29332041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders.
    Maeda J; Zhang MR; Okauchi T; Ji B; Ono M; Hattori S; Kumata K; Iwata N; Saido TC; Trojanowski JQ; Lee VM; Staufenbiel M; Tomiyama T; Mori H; Fukumura T; Suhara T; Higuchi M
    J Neurosci; 2011 Mar; 31(12):4720-30. PubMed ID: 21430171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.
    van Olst L; Verhaege D; Franssen M; Kamermans A; Roucourt B; Carmans S; Ytebrouck E; van der Pol SMA; Wever D; Popovic M; Vandenbroucke RE; Sobrino T; Schouten M; de Vries HE
    Neurobiol Aging; 2020 May; 89():89-98. PubMed ID: 32008854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microglial Activation and Connectivity in Alzheimer Disease and Aging.
    Rauchmann BS; Brendel M; Franzmeier N; Trappmann L; Zaganjori M; Ersoezlue E; Morenas-Rodriguez E; Guersel S; Burow L; Kurz C; Haeckert J; Tatò M; Utecht J; Papazov B; Pogarell O; Janowitz D; Buerger K; Ewers M; Palleis C; Weidinger E; Biechele G; Schuster S; Finze A; Eckenweber F; Rupprecht R; Rominger A; Goldhardt O; Grimmer T; Keeser D; Stoecklein S; Dietrich O; Bartenstein P; Levin J; Höglinger G; Perneczky R
    Ann Neurol; 2022 Nov; 92(5):768-781. PubMed ID: 36053756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.
    Mandrekar-Colucci S; Karlo JC; Landreth GE
    J Neurosci; 2012 Jul; 32(30):10117-28. PubMed ID: 22836247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes.
    Zhao Q; Wu X; Yan S; Xie X; Fan Y; Zhang J; Peng C; You Z
    J Neuroinflammation; 2016 Oct; 13(1):259. PubMed ID: 27716270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microglial response to increasing amyloid load saturates with aging: a longitudinal dual tracer in vivo μPET-study.
    Blume T; Focke C; Peters F; Deussing M; Albert NL; Lindner S; Gildehaus FJ; von Ungern-Sternberg B; Ozmen L; Baumann K; Bartenstein P; Rominger A; Herms J; Brendel M
    J Neuroinflammation; 2018 Nov; 15(1):307. PubMed ID: 30400912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice.
    Jiang T; Zhang YD; Chen Q; Gao Q; Zhu XC; Zhou JS; Shi JQ; Lu H; Tan L; Yu JT
    Neuropharmacology; 2016 Jun; 105():196-206. PubMed ID: 26802771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
    Skerrett R; Pellegrino MP; Casali BT; Taraboanta L; Landreth GE
    J Biol Chem; 2015 Aug; 290(35):21591-602. PubMed ID: 26163517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice.
    Yamanaka M; Ishikawa T; Griep A; Axt D; Kummer MP; Heneka MT
    J Neurosci; 2012 Nov; 32(48):17321-31. PubMed ID: 23197723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the In Vivo Relationship Between Cerebral Hypometabolism, Tau Deposition, TSPO Expression, and Synaptic Density in a Tauopathy Mouse Model: a Multi-tracer PET Study.
    Endepols H; Anglada-Huguet M; Mandelkow E; Schmidt Y; Krapf P; Zlatopolskiy BD; Neumaier B; Mandelkow EM; Drzezga A
    Mol Neurobiol; 2022 Jun; 59(6):3402-3413. PubMed ID: 35312967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effect of mitochondrial translocator protein ligand in a mouse model of tauopathy.
    Fairley LH; Sahara N; Aoki I; Ji B; Suhara T; Higuchi M; Barron AM
    J Neuroinflammation; 2021 Mar; 18(1):76. PubMed ID: 33740987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARγ activation ameliorates cognitive impairment and chronic microglial activation in the aftermath of r-mTBI.
    Pearson A; Koprivica M; Eisenbaum M; Ortiz C; Browning M; Vincennie T; Tinsley C; Mullan M; Crawford F; Ojo J
    J Neuroinflammation; 2024 Aug; 21(1):194. PubMed ID: 39097742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased tauopathy drives microglia-mediated clearance of beta-amyloid.
    Chen W; Abud EA; Yeung ST; Lakatos A; Nassi T; Wang J; Blum D; Buée L; Poon WW; Blurton-Jones M
    Acta Neuropathol Commun; 2016 Jun; 4(1):63. PubMed ID: 27339073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual regional associations between Aβ-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies.
    Finze A; Biechele G; Rauchmann BS; Franzmeier N; Palleis C; Katzdobler S; Weidinger E; Guersel S; Schuster S; Harris S; Schmitt J; Beyer L; Gnörich J; Lindner S; Albert NL; Wetzel CH; Rupprecht R; Rominger A; Danek A; Burow L; Kurz C; Tato M; Utecht J; Papazov B; Zaganjori M; Trappmann LK; Goldhardt O; Grimmer T; Haeckert J; Janowitz D; Buerger K; Keeser D; Stoecklein S; Dietrich O; Morenas-Rodriguez E; Barthel H; Sabri O; Bartenstein P; Simons M; Haass C; Höglinger GU; Levin J; Perneczky R; Brendel M
    Mol Psychiatry; 2023 Oct; 28(10):4438-4450. PubMed ID: 37495886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.